Loading organizations...
§ Private Profile · Office3.02, 3rd Floor, White Collar Factory, Old Street Yard, London, England, EC1Y 8AF
Thriva is a technology company.
Thriva has raised $11.9M across 3 funding rounds.
Key people at Thriva.
Thriva has raised $11.9M in total across 3 funding rounds.
Thriva provides accessible at-home blood testing services, empowering individuals with a deeper understanding of their internal health. The company offers insights into over 75 health markers, delivering personalized reports and actionable guidance for lifestyle adjustments. It integrates data from various wearables and fitness applications into a comprehensive Healthspan Dashboard, enabling users to track trends and make informed decisions about their well-being and performance.
The company was co-founded by Hamish Grierson, Tom Livesey, and Eliot Brooks, launching around 2015. Their founding insight stemmed from observing a significant disparity between increasing lifespans and stagnant healthspans, identifying a critical absence of user-friendly tools that allow individuals to proactively manage their health before the onset of serious conditions. This led to the creation of a platform dedicated to demystifying internal biological data.
Thriva serves individuals who seek to optimize their health, enhance longevity, and improve overall vitality through preventative measures. The company envisions a future where proactive health management is standard, offering the tools, insights, and support necessary for people to understand their bodies, take confident action, and ultimately experience more years in good health. It aims to make living better, for longer, a tangible reality for its users.
Thriva has raised $11.9M across 3 funding rounds. Most recently, it raised $4.9M Series A Extension in May 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 22, 2020 | $4.9M Series A Plus | Ricardo Schaefer | Guinness Asset Management, Pembroke VCT | Announced |
| May 1, 2020 | $5M Series A | — | Atomico, DST Global, Mosaic Ventures, Target Global, Errol Damelin, Paul Forster | Announced |
| Jun 1, 2017 | $2M Seed | — | 01 Advisors, Andreessen Horowitz, Coatue, Contrary Capital, DCM, Energize Ventures, Entrepreneur First, Episode 1 Ventures, Felicis Ventures, Felix Capital, Floodgate, LGF, Liquid 2 Ventures, Long Journey Ventures, Octopus Ventures, Outrun Ventures, Pareto Holdings, Project A, TDK Ventures, Voyager Ventures, Wave Capital, Andrew Robb, John Johnson, NIC Brisbourne, RON Pragides, Ryan ORR, Will Brooks, Alex Chesterman, Simon Franks, Taavet Hinrikus, 500 Startups, London Co Investment Fund, Carlos Eduardo | Announced |
Thriva is a healthtech startup founded in 2016 that provides at-home blood testing subscriptions, delivering personalized health insights, diagnostics, and actionable recommendations to empower proactive health management.[2][3] It serves consumers seeking to optimize energy, fitness, longevity, or overall vitality, while also offering B2B solutions to entities like the NHS and insurers, solving the problem of inaccessible, preventative health monitoring by enabling real-time tracking to prevent issues before they require hospitalization.[2][3] With over 200,000 customers supported, Thriva combines a user-friendly app, autodraw blood collection device, and doctor-reviewed reports for ongoing progress tracking, demonstrating strong growth in the direct-to-consumer health space.[3][4]
Thriva was founded in 2016 (with roots tracing to 2015) by Hamish Grierson, driven by his personal fascination with health that began 11 years prior, leading him into self-improvement and developing tools for sustained energy and productivity.[2][3] This "rabbit hole" of health optimization inspired a platform for upstream, preventative care through at-home blood testing, shifting from reactive hospital visits to real-time personal insights.[2] Early traction built on a subscription model, evolving to include AI-driven personalization, a MHRA-registered Class One medical device for automated recommendations, and B2B integrations, marking pivotal moments in scaling from consumer-facing tests to enterprise partnerships.[2]
(Note: Thriva Technologies in search result [1] appears to be a distinct entity focused on digital content services, unrelated to this healthtech company.[1])
Thriva rides the wave of preventative healthtech and personalized medicine, fueled by post-pandemic demand for at-home diagnostics, AI advancements, and consumer shift toward data-driven wellness over reactive care.[2][3] Timing aligns with wearable tech limitations—smartwatches track surface metrics, but Thriva's blood analysis provides deeper, "articulate" internal truths, validated by extensive studies.[4] Favorable market forces include rising longevity focus, athlete-inspired optimization for everyday users, and regulatory nods like MHRA approval, positioning Thriva to influence ecosystems by powering public health (NHS) and insurance while normalizing proactive testing for 200,000+ users.[2][3]
Thriva is poised to expand its AI personalization and B2B footprint, potentially integrating deeper with wearables or expanding test profiles amid booming demand for longevity and peak performance tools.[2][4] Trends like computational health advances and regulatory easing for home devices will accelerate growth, evolving Thriva from a subscription pioneer to a core platform in everyday health empowerment—keeping its founding promise of upstream prevention alive in a vitality-obsessed world.[2][3]
Thriva has raised $11.9M in total across 3 funding rounds.
Thriva's investors include Ricardo Schaefer, Guinness Asset Management, Pembroke VCT, Atomico, DST Global, Mosaic Ventures, Target Global, Errol Damelin, Paul Forster, 01 Advisors, Andreessen Horowitz, Coatue.
Key people at Thriva.
